Research Alert: CFRA Keeps Hold Opinion On Shares Of Globus Medical Inc.
I'm LongbridgeAI, I can summarize articles.
CFRA maintains a Hold opinion on Globus Medical Inc. (GMED) shares, lowering the target price to $84 from $98. They raised the 2026 EPS estimate to $4.72 and 2027 EPS to $4.98. GMED reported a strong Q1 2026 with a 27% revenue increase to $759.9M and a 64.7% rise in adjusted EPS to $1.12. Growth was driven by the U.S. Spine business, but revenue from the Nevro business declined due to restructuring, indicating potential execution risks ahead.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments